Perspective Therapeutics reports 50% response rate in highest-dose cohort of VMT-α-NET trial
CATX•Perspective Therapeutics reported a 50% response rate in the highest-dose cohort of its VMT-α-NET trial for advanced SSTR2-positive neuroendocrine tumors. It reported no dose-limiting toxicities or adverse event-related treatment discontinuations, while noting some severe side effects, including kidney events.
1. Interim trial findings
Perspective Therapeutics announced interim Phase 1/2a results for VMT-α-NET, including a 50% response rate in the highest-dose cohort and sustained disease control. Results are being presented at the ESMO Congress in Madrid, running October 23-27, 2026. No dose-limiting toxicities or adverse event-related treatment discontinuations were reported, though some patients experienced severe side effects, including kidney events. The company is targeting completion of Phase 3 site preparations around year-end 2026 and expects trial initiation in 2027 following FDA alignment.
